Ernexa Therapeutics Inc. Proceeds from Notes Payable
Ernexa Therapeutics Inc. (ERNA) reported Proceeds from Notes Payable of $2.25 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-08-06
- Ernexa Therapeutics Inc. proceeds from notes payable for the quarter ending 2025-12-31 was $0.00.
- Ernexa Therapeutics Inc. proceeds from notes payable for the quarter ending 2025-09-30 was $0.00.
- Ernexa Therapeutics Inc. proceeds from notes payable for the quarter ending 2025-06-30 was $0.00.
- Ernexa Therapeutics Inc. proceeds from notes payable for the quarter ending 2025-03-31 was $2.25M.
- Ernexa Therapeutics Inc. proceeds from notes payable for fiscal 2025 was $2.25M.
- Ernexa Therapeutics Inc. proceeds from notes payable for fiscal 2023 was $1.50M.
- Ernexa Therapeutics Inc. proceeds from notes payable for fiscal 2022 was $0.00.
- Ernexa Therapeutics Inc. proceeds from notes payable for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $2.25M 10-K · filed 2026-03-13 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $2.25M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.25M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $2.25M 10-Q · filed 2026-05-11 | |||
| 2023-12-31 | $1.50M 10-K · filed 2024-03-14 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 | |||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-01 | $0.00 derived: sum of 2 quarters · filed 2022-07-01 | $0.00 10-K/A · filed 2022-07-01 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-13 | |||
| 2020-12-31 | $95.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-01 | $95.00 derived: sum of 2 quarters · filed 2022-07-01 | $310.00K 10-K/A · filed 2022-07-01 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $309.90K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $309.90K 10-Q · filed 2021-08-13 | |||
| 2015-03-31 | $74.00K 10-Q · filed 2015-05-08 | $1.80M derived: sum of 2 quarters · filed 2015-05-08 | $3.10M derived: sum of 3 quarters · filed 2015-05-08 | $5.36M derived: sum of 4 quarters · filed 2015-05-08 |
| 2014-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $3.03M derived: sum of 2 quarters · filed 2015-03-27 | $5.29M derived: sum of 3 quarters · filed 2015-03-27 | $6.05M 10-K · filed 2015-03-27 |
| 2014-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $3.56M derived: sum of 2 quarters · filed 2014-11-07 | $4.32M 10-Q · filed 2014-11-07 | $5.64M derived: sum of 4 quarters · filed 2015-05-08 |
| 2014-06-30 | $2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $3.02M 10-Q · filed 2014-08-14 | $4.34M derived: sum of 3 quarters · filed 2015-05-08 | $4.50M derived: sum of 4 quarters · filed 2015-05-08 |
| 2014-03-31 | $764.00K 10-Q · filed 2015-05-08 | $2.08M derived: sum of 2 quarters · filed 2015-05-08 | $2.24M derived: sum of 3 quarters · filed 2015-05-08 | $2.37M derived: sum of 4 quarters · filed 2015-05-08 |
| 2013-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $1.48M derived: sum of 2 quarters · filed 2015-03-27 | $1.61M derived: sum of 3 quarters · filed 2015-03-27 | $1.61M 10-K · filed 2015-03-27 |
| 2013-09-30 | $162.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $290.00K derived: sum of 2 quarters · filed 2014-11-07 | $290.00K 10-Q · filed 2014-11-07 | $290.00K derived: sum of 4 quarters · filed 2014-11-07 |
| 2013-06-30 | $128.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $128.00K 10-Q · filed 2014-08-14 | $128.00K derived: sum of 3 quarters · filed 2014-08-14 | |
| 2013-03-31 | $0.00 10-Q · filed 2014-05-15 | $0.00 derived: sum of 2 quarters · filed 2014-05-15 | ||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-31 | $0.00 10-K · filed 2014-03-31 | ||
| 2012-09-30 | $0.00 10-Q · filed 2013-11-14 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | $123.00K 10-K · filed 2013-03-29 | ||
| 2011-09-30 | $123.00K 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |